AGEN
USDAgenus Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$3.840
Kõrge
$3.980
Madal
$3.700
Maht
0.33M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
126.8M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
0.46M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.
France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer
Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balstilimab (BOT/BAL) is now available to eligible patients with refractory microsatellite‑stable
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with...
HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $23 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus with a Buy and maintains $23 price target.
Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight
Webcast details updated from the August 11th release Webcast on Wednesday, August 27, 2025 at 4:00 p.m. EST Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced an update to its
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.